10:55 AM EDT, 10/22/2025 (MT Newswires) -- Thermo Fisher Scientific ( TMO ) raised its full-year outlook on Wednesday as the medical-device manufacturer reported better-than-expected fiscal third-quarter results.

The company now anticipates adjusted earnings of $22.60 to $22.86 per share and revenue between $44.1 billion and $44.5 billion for 2025, Chief Executive Marc Casper said during an earnings call, according to a FactSet transcript. Thermo Fisher previously projected full-year adjusted EPS of $22.22 to $22.84 and revenue of $43.6 billion to $44.2 billion, Casper told analysts in July.

The current consensus on FactSet is for non-GAAP EPS of $22.51 and sales of $43.99 billion for 2025.

Foreign exchange is now pegged to be a $230 million tailwind to revenue and negatively impact adjusted EPS by $0.37, Chief Financial Officer Stephen Williamson said on the Wednesday call.

Thermo Fisher posted adjusted EPS of $5.79 for the quarter ended Sept. 27, up from $5.28 a year earlier and above the Street's view of $5.50. Revenue grew 5% to $11.12 billion, surpassing the average analyst estimate of $10.92 billion.

By segment, life sciences and solutions revenue improved 8% year on year to $2.59 billion, led by a bioproduction business, according to Williamson. Revenue in the analytical instruments division advanced 5% to $1.89 billion, buoyed by led by electron microscopy and chromatography and mass spectrometry, the CFO added.

Laboratory products and biopharma services' sales rose 4% to $5.97 billion, while specialty diagnostics moved higher to $1.17 billion from $1.13 billion the year before.

Price: 559.88, Change: +1.89, Percent Change: +0.34